相关实验视频

Updated: Jul 4, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

布罗利祖马布组合治疗NSCLC的有效性和预测因素在现实世界的实践中

Magdalena Knetki-Wróblewska¹, Rafał Dziadziuszko², Tomasz Jankowski³

¹Department of Lung Cancer and Chest Tumours, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Frontiers in oncology

|February 7, 2024

概括

布罗利祖马布加化疗对非小细胞肺癌患者有好处,即使编程死亡配体1 (PD-L1) 表达率低. 现实世界的数据显示了临床益处,并确定了预后因素,如表现状态和转移程度.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
临床研究临床研究

背景情况:

与化疗相结合的 pembrolizumab 是非小细胞肺癌 (NSCLC) 的标准,PD-L1 <50%.
现实世界的疗效和预测因素,特别是低PD-L1表达,需要评估.

研究的目的:

评估pembrolizumab加化学疗法在IV期NSCLC中的实际有效性.
确定预测和预后因素,重点关注PD-L1表达低的患者.

主要方法:

在339名IV期NSCLC患者的多中心追溯分析中.
评估整体应答率 (ORR),无进展生存率 (PFS) 和整体生存率 (OS).
多变量分析以确定影响OS的因素.

主要成果:

总人口:ORR 40.6%,中位数PFS 13个月,中位数OS 16.8个月.
51%的患者具有低PD-L1表达.
对OS的负面预后因素包括表现不佳状态 (ECOG 1 vs. 0),高中性粒细胞与淋巴细胞比率 (NLR>3),肝/骨转移,体重减轻和大损伤直径总和.

结论:

免疫化学疗法在现实世界NSCLC患者中提供临床益处,无论PD-L1表达或组织学如何.
临床病理学因素,如表现状态和转移部位显著影响预后.

关键词:

在NSCLCLC中,我们可以看到.PD-L1 低表达性的免疫化学疗法免疫化学疗法这就是Pembrolizumab.现实世界的数据数据.

更多相关视频

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.